TY  - JOUR
TI  - First line PD-1 inhibitor, Serplulimab Plus Chemoradiotheraphy for Extensive Stage Thymic Carcinoma: A Case Report
AU  - HAFIZ, M.
AU  - GHANIE ICKSAN, A.
AU  - ANDARINI, S.
AU  - HARLIVASARI, A.D.
JO  - Turk J Oncol
PY  - 2026
VL  - 41
SP  - 160
EP  - 164
DO  - 10.5505/tjo.2026.4783
ER  -